Advertisement
Australia markets closed
  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     
  • AUD/USD

    0.6450
    -0.0001 (-0.02%)
     
  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     
  • OIL

    81.95
    +0.05 (+0.06%)
     
  • GOLD

    2,313.30
    -33.10 (-1.41%)
     
  • Bitcoin AUD

    102,564.77
    +175.21 (+0.17%)
     
  • CMC Crypto 200

    1,420.03
    +5.27 (+0.37%)
     

Is This Biotech Stock a Buy Following a Landmark Approval?

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.